Enliven CMO exercises options, sells 5,000 shares

Enliven Therapeutics chief medical officer Helen Louise Collins exercised stock options and sold shares in a pre-planned set of trades.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Enliven Therapeutics chief medical officer Helen Louise Collins exercised stock options and sold shares in a pre-planned set of trades. On April 17, 2026, she exercised options to acquire 5,000 shares of common stock at $2.48 per share, then sold 5,000 shares in open-market transactions at weighted average prices around $45.81–$48.06, all under a Rule 10b5-1 trading plan adopted on October 19, 2025. After these transactions, she directly held 25,000 shares of Enliven common stock.

Insider Trade Summary 10b5-1

Exercise and Sale: 5,000 shares ($226K approx. pre-tax spread)

Exercise and Sale 5 txns

Insider Collins Helen Louise

Role CHIEF MEDICAL OFFICER

Sold 5,000 shs ($238K)

Approx. gross sale proceeds $238K

Approx. exercise cost $12K

Approx. pre-tax spread $226K

Type	Security	Shares	Price	Value
Exercise	Stock Option (right to buy)	5,000	$0.00	$0.00
Exercise	Common Stock	5,000	$2.48	$12K
Sale	Common Stock	140	$45.8107	$6K
Sale	Common Stock	2,419	$47.3896	$115K
Sale	Common Stock	2,441	$48.0555	$117K

Holdings After Transaction: Stock Option (right to buy) — 131,268 contracts (Direct); Common Stock — 25,000 shares (Direct)

Footnotes (7)

F1. The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025.
F2. Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
F3. This transaction was executed in multiple trades at prices ranging from $45.525 to $46.38. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F4. This transaction was executed in multiple trades at prices ranging from $46.8218 to $47.8166. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F5. This transaction was executed in multiple trades at prices ranging from $47.8303 to $48.4936. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F6. These securities are RSUs. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
F7. All of the shares subject to this option are fully vested and exercisable as of the date hereof.

Key Figures

Shares sold: 5,000 shares Sale prices: $45.81–$48.06 per share Options exercised: 5,000 shares +3 more

6 metrics

Shares sold 5,000 shares Open-market sales on April 17, 2026

Sale prices $45.81–$48.06 per share Weighted average prices across three trades

Options exercised 5,000 shares Stock options converted to common stock

Exercise price $2.48 per share Stock option exercise price

Post-transaction holdings 25,000 shares Common stock directly held after trades

Option expiration June 17, 2031 Expiration date for the stock option grant

Key Terms

Rule 10b5-1 trading plan, restricted stock units (RSUs), weighted average sale price, Stock Option (right to buy), +1 more

5 terms

Rule 10b5-1 trading plan regulatory

"effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

restricted stock units (RSUs) financial

"Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right"

Restricted stock units (RSUs) are a type of company promise to give employees shares of stock in the future, usually after certain conditions like working for a set time. They are like a gift promised today that you receive later, which can become valuable if the company's stock price goes up. RSUs matter because they are a way companies reward employees and can be a significant part of compensation.

weighted average sale price financial

"The price reported above reflects the weighted average sale price."

Stock Option (right to buy) financial

"security_title": "Stock Option (right to buy)""

fully vested and exercisable financial

"All of the shares subject to this option are fully vested and exercisable as of the date hereof."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Enliven Therapeutics (ELVN) CMO Helen Collins do in this Form 4?

Helen Collins exercised stock options for 5,000 Enliven shares and sold 5,000 shares in the open market. These trades occurred on April 17, 2026 under a pre-arranged Rule 10b5-1 trading plan.

How many Enliven (ELVN) shares did the CMO sell and at what prices?

The CMO sold a total of 5,000 Enliven common shares. Weighted average sale prices ranged from about $45.81 to $48.06 per share across multiple open-market transactions executed the same day.

What stock options did Enliven’s CMO exercise in this filing?

She exercised stock options covering 5,000 shares of Enliven common stock at an exercise price of $2.48 per share. All option shares were fully vested and exercisable as of the transaction date.

How many Enliven (ELVN) shares does the CMO own after these transactions?

Following the reported option exercise and related sales, Helen Collins directly holds 25,000 shares of Enliven Therapeutics common stock. This figure reflects her position after all transactions on April 17, 2026.

Were the Enliven (ELVN) insider trades made under a Rule 10b5-1 plan?

Yes. The option exercise and share sales were carried out under a Rule 10b5-1 trading plan. The filing notes this plan was adopted by Helen Collins on October 19, 2025 before the April 2026 transactions.

What does the Rule 10b5-1 trading plan mean for these Enliven trades?

A Rule 10b5-1 trading plan allows pre-scheduled trades, reducing timing discretion by the insider. The filing states Collins’ option exercise and share sales followed such a plan adopted in October 2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 04/21/2026 - 08:40 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Collins Helen Louise

(Last)

(First)

(Middle)

C/O ENLIVEN THERAPEUTICS, INC.

6200 LOOKOUT ROAD

(Street)

BOULDER

COLORADO

80301

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Enliven Therapeutics, Inc. [ ELVN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	CHIEF MEDICAL OFFICER

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	04/17/2026		M⁽¹⁾		5,000	A	$2.48	30,000⁽²⁾	D
Common Stock	04/17/2026		S⁽¹⁾		140	D	$45.8107⁽³⁾	29,860⁽²⁾	D
Common Stock	04/17/2026		S⁽¹⁾		2,419	D	$47.3896⁽⁴⁾	27,441⁽²⁾	D
Common Stock	04/17/2026		S⁽¹⁾		2,441	D	$48.0555⁽⁵⁾	25,000⁽⁶⁾	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (right to buy)	$2.48	04/17/2026		M⁽¹⁾			5,000	⁽⁷⁾	06/17/2031	Common Stock	5,000	$0	131,268	D

Explanation of Responses:

1. The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025.

2. Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

3. This transaction was executed in multiple trades at prices ranging from $45.525 to $46.38. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

4. This transaction was executed in multiple trades at prices ranging from $46.8218 to $47.8166. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

5. This transaction was executed in multiple trades at prices ranging from $47.8303 to $48.4936. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

6. These securities are RSUs. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

7. All of the shares subject to this option are fully vested and exercisable as of the date hereof.

	/s/ Ben Hohl, by power of attorney	04/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR